Tue, January 8, 2013
Mon, January 7, 2013
Sun, January 6, 2013
Fri, January 4, 2013
Thu, January 3, 2013
Wed, January 2, 2013
Mon, December 31, 2012
Fri, December 28, 2012
[ Fri, Dec 28th 2012 ] - Market Wire
Verisante Issues Stock Options
Thu, December 27, 2012
Wed, December 26, 2012
[ Wed, Dec 26th 2012 ] - Market Wire
30 p.m. ET
Mon, December 24, 2012
Fri, December 21, 2012
Thu, December 20, 2012
[ Thu, Dec 20th 2012 ] - Market Wire
A View from the Top
Wed, December 19, 2012
Tue, December 18, 2012
Mon, December 17, 2012
Fri, December 14, 2012
Thu, December 13, 2012
Wed, December 12, 2012
Tue, December 11, 2012
Mon, December 10, 2012

Regeneron Announces January 2013 Investor Conference Presentations


//health-fitness.news-articles.net/content/2012/ .. uary-2013-investor-conference-presentations.html
Published in Health and Fitness on Thursday, December 20th 2012 at 6:46 GMT by Market Wire   Print publication without navigation


Regeneron Announces January 2013 Investor Conference Presentations -- TARRYTOWN, N.Y., Dec. 20, 2012 /PRNewswire/ --

TARRYTOWN, N.Y., Dec. 20, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: [ REGN ]) will webcast management presentations at the following investor conferences:

  • Goldman Sachs Healthcare CEOs Unscripted:  A View from the Top on Thursday, January 3, 2013.  The session is scheduled for 3:15 p.m. Eastern Time.
  • 31st Annual J. P. Morgan Healthcare Conference on Tuesday, January 8, 2013.  The presentation is scheduled for 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

The sessions may be accessed through the Company's web site, [ www.regeneron.com ], on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

Contact Information:




Michael Aberman, M.D.                       

Peter Dworkin

Investor Relations                                

Corporate Communications                           

914.847.7799                                           

914.847.7640             

[ michael.aberman@regeneron.com ]             

[ peter.dworkin@regeneron.com ]

 

SOURCE Regeneron Pharmaceuticals, Inc.



RELATED LINKS
[ http://www.regeneron.com ]

Publication Contributing Sources